Compare BHVN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHVN | FTRE |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | 14000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2022 | 2023 |
| Metric | BHVN | FTRE |
|---|---|---|
| Price | $11.39 | $13.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | ★ $29.08 | $14.06 |
| AVG Volume (30 Days) | ★ 1.7M | 1.5M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $7.48 | $3.97 |
| 52 Week High | $18.57 | $18.67 |
| Indicator | BHVN | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 68.12 | 56.26 |
| Support Level | $10.75 | $9.01 |
| Resistance Level | $11.92 | $18.26 |
| Average True Range (ATR) | 0.66 | 0.65 |
| MACD | 0.20 | -0.24 |
| Stochastic Oscillator | 99.48 | 13.44 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.